Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Expanded protocols promote early detection in high-risk patients and prevent hospital outbreaks of Candida auris.

Antipsychotics are the best defense against relapse in schizophrenia ... clozapine for people who the guidelines say have to ...

New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to ...

The goal in treating ulcerative colitis is to reduce the inflammation, hopefully leading to remission. The two leading treatment options are medication and surgery. Approximately 70 percent of ...

a second-generation antipsychotic often used for treatment-resistant schizophrenia, also ranked low (0.12). For reference, a significant or noticeable SMD result would be anything 0.5 or higher ...

Scott suffers from chronic treatment-resistant schizophrenia. He will continue to be held at a secure psychiatric facility. The Alberta Review Board will conduct a hearing in the next 45 days ...

A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...

Preliminary results demonstrated a dose-dependent effect of ANAVEX ® 3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX ® 3-71 compared to placebo resulted in ...

Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or ...

The data published in The Lancet is being heralded as a big breakthrough in the treatment of cervical cancer and uses readily available chemotherapy drugs, given to patients before they receive ...